Univercells and Repligen Corporation have teamed up to integrate real-time monitoring capabilities, while enhancing the development and manufacturing of viral vectors and vaccines.
By combining four crucial devices for process analytical technology (PAT) applications, the companies will eliminate the need for manual nutrient testing, while significantly increasing data resolution.
The MAVEN Real Time Glucose Control Platform, which Repligen recently acquired from 908 Devices, will be used to perform real-time monitoring of glucose and lactate in the range of scale-X bioreactors for adherent cell culture processes.
The technology allows the control of glucose and lactate concentrations during cell culture and fermentation without removing any media volume from the bioreactor.
By gaining real-time insights into cellular metabolism, it's easier to optimise media and develop feeding/control strategies.
Users can detect and react to process changes with monitoring of glucose and lactate as often as every 2 minutes and up to 720 glucose-lactate data points per day.
“This collaboration brings real time process analytical technology (PAT) to our scale-X bioreactors, eliminating manual nutrient testing and significantly increasing data resolution," noted said Marie Jourdan, Director of Product Management at Univercells Technologies.
"With more frequent and automatic measurements, we can feed data into our Skaia vision application software model for an even more accurate estimation of cell growth,”
“Compatibility of technologies is critical to commercialising advanced therapies,” said Wolfgang Kuennecke, VP, Bioanalytic, Enzymatic Analyzers from Repligen.
“In this alignment, we have combined MAVEN and the scale-X bioreactors via a custom diffusion manifold so that developers can expand their toolbox simply. This integration helps developers to concentrate on the needs of their cells and create the optimum process conditions for their growth.”
As part of this collaboration, the team is actively generating data to support the integration of these technologies.
The team is also engaging with potential beta testers to validate use cases and support the development of this solution.
In the meantime, the scale-X bioreactor portfolio and MAVEN advanced monitoring system are taking immediate inquiries.
